dc.contributor.author
Demircan, Kamil
dc.contributor.author
Bengtsson, Ylva
dc.contributor.author
Chillon, Thilo Samson
dc.contributor.author
Vallon-Christersson, Johan
dc.contributor.author
Sun, Qian
dc.contributor.author
Larsson, Christer
dc.contributor.author
Malmberg, Martin
dc.contributor.author
Saal, Lao H.
dc.contributor.author
Rydén, Lisa
dc.contributor.author
Borg, Åke
dc.contributor.author
Manjer, Jonas
dc.contributor.author
Schomburg, Lutz
dc.date.accessioned
2025-09-17T08:40:12Z
dc.date.available
2025-09-17T08:40:12Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/49350
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-49072
dc.description.abstract
Introduction: Low serum selenium and altered tumour RNA expression of certain selenoproteins are associated with a poor breast cancer prognosis. Selenoprotein expression stringently depends on selenium availability, hence circulating selenium may interact with tumour selenoprotein expression. However, there is no matched analysis to date. Methods: This study included 1453 patients with newly diagnosed breast cancer from the multicentric prospective Sweden Cancerome Analysis Network - Breast study. Total serum selenium, selenoprotein P and glutathione peroxidase 3 were analysed at time of diagnosis. Bulk RNA-sequencing was conducted in matched tumour tissues. Fully adjusted Cox regression models with an interaction term were employed to detect dose-dependent interactions of circulating selenium with the associations of tumour selenoprotein mRNA expression and mortality. Results: 237 deaths were recorded within similar to 9 years follow-up. All three serum selenium biomarkers correlated positively (p < 0.001). All selenoproteins except for GPX6 were expressed in tumour tissues. Single cell RNA-sequencing revealed a heterogeneous expression pattern in the tumour microenvironment. Circulating selenium correlated positively with tumour SELENOW and SELENON expression (p < 0.001). In fully adjusted models, the associations of DIO1, DIO3 and SELENOM with mortality were dose-dependently modified by serum selenium (p < 0.001, p = 0.020, p = 0.038, respectively). With increasing selenium, DIO1 and SELENOM associated with lower, whereas DIO3 expression associated with higher mortality. Association of DIO1 with lower mortality was only apparent in patients with high selenium [above median (70.36 mu g/L)], and the HR (95%CI) for one-unit increase in log(FPKM + 1) was 0.70 (0.50-0.98). Conclusions: This first unbiased analysis of serum selenium with the breast cancer selenotranscriptome identified an effect-modification of selenium on the associations of DIO1, SELENOM, and DIO3 with prognosis. Selenium substitution in patients with DIO1-expressing tumours merits consideration to improve survival.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
selenoproteins
en
dc.subject
glutathione peroxidase
en
dc.subject
thyroid hormones
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Matched analysis of circulating selenium with the breast cancer selenotranscriptome: a multicentre prospective study
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
658
dcterms.bibliographicCitation.doi
10.1186/s12967-023-04502-y
dcterms.bibliographicCitation.journaltitle
Journal of Translational Medicine
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
21
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
37741974
dcterms.isPartOf.eissn
1479-5876